Latest Pharma and Biotech News
Pharmaceutical
10 September 2024 The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer.
Today's issue
Refine Search
Biotechnology
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
Biotechnology
California, USA-based biotech BridgeBio Pharma saw its shares dip 4% to $29.60 yesterday on disappointing clinical results and the company’s decision to drop an early-stage candidate. 11 September 2024
Pharmaceutical
Shares in Novo Nordisk frequently jump upwards when the latest data on the company’s blockbuster obesity drug Wegovy (semaglutide) are released. 11 September 2024
Biotechnology
Ionis Pharmaceuticals has announced plans to raise $500 million through a public offering. 11 September 2024
Pharmaceutical
Terns Pharmaceuticals, a specialist in small molecule treatments for serious diseases, is to raise $150 million via a public offering. 11 September 2024
Pharmaceutical
The research based pharmaceutical industry has welcomed Mario Draghi’s report, published by the European Commission, outlining proposals on how Europe can regain its competitive edge and the critical role of innovative industries in achieving this. 11 September 2024
Pharmaceutical
Germany’s Bayer has presented results from the Phase III OASIS 3 study further supporting efficacy data and sustained safety data of elinzanetant over 52 weeks in vasomotor symptoms (VMS). 11 September 2024
Biotechnology
US biotech Regeneron Pharmaceuticals has announced five-year results from the final pre-specified overall survival (OS) analysis of the Phase III EMPOWER-Lung 1 trial. 11 September 2024
Biotechnology
Sanofi and Regeneron’s all-conquering inflammatory diseases drug Dupixent (dupilumab) has shown its worth in another disease. 11 September 2024
Biotechnology
Atara Biotherapeutics has appointed Cokey Nguyen as its new president and chief executive. 11 September 2024
Pharmaceutical
Even as emerging signs of a thaw in the broader Indian start-up funding landscape were evident, the Competition Commission of India (CCI) has tightened its exemption list under new combination rules. 11 September 2024
Pharmaceutical
Eli Lilly has announced positive results from two Phase III trials evaluating its once-weekly insulin efsitora alfa (efsitora) against the daily insulin degludec for adults with type 1 and type 2 diabetes. 11 September 2024
Biotechnology
Viridian Therapeutics has reported positive topline data from its Phase III THRIVE clinical trial of veligrotug, an intravenous treatment for thyroid eye disease (TED). 11 September 2024
Biotechnology
MAIA Biotechnology yesterday announced favorable interim survival benefit from its lead clinical candidate THIO, a telomere-targeting treatment for patients with advanced 11 September 2024
Biotechnology
US gene therapies developer Affinia Therapeutics has appointed Rami Daoud as chief business and financial officer. 11 September 2024
Pharmaceutical
New obesity drugs from public and private companies are emerging to challenge the leading positions of Denmark-based Novo Nordisk and US pharma major Eli Lilly in a GLP-1 drug market that is estimated to reach more than $200 billion in annual sales by 2031. 11 September 2024
Pharmaceutical
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
Pharmaceutical
Swiss pharma giant Roche today announced the opening of the new pharmaceutical research and development center at its global headquarters in Basel. 10 September 2024
Pharmaceutical
Roivant today announced its previously undisclosed pipeline program mosliciguat, a potential first-in-class, inhaled, once-daily sGC activator with targeted delivery to the lungs via dry powder inhaler, at Pulmovant. 10 September 2024
Biotechnology
Californian companies Gilead Sciences and Genesis Therapeutics have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. 10 September 2024
All news
Biotechnology
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
Biotechnology
California, USA-based biotech BridgeBio Pharma saw its shares dip 4% to $29.60 yesterday on disappointing clinical results and the company’s decision to drop an early-stage candidate. 11 September 2024
Pharmaceutical
Shares in Novo Nordisk frequently jump upwards when the latest data on the company’s blockbuster obesity drug Wegovy (semaglutide) are released. 11 September 2024
Biotechnology
Ionis Pharmaceuticals has announced plans to raise $500 million through a public offering. 11 September 2024
Pharmaceutical
Terns Pharmaceuticals, a specialist in small molecule treatments for serious diseases, is to raise $150 million via a public offering. 11 September 2024
Pharmaceutical
The research based pharmaceutical industry has welcomed Mario Draghi’s report, published by the European Commission, outlining proposals on how Europe can regain its competitive edge and the critical role of innovative industries in achieving this. 11 September 2024
Pharmaceutical
Germany’s Bayer has presented results from the Phase III OASIS 3 study further supporting efficacy data and sustained safety data of elinzanetant over 52 weeks in vasomotor symptoms (VMS). 11 September 2024
Biotechnology
US biotech Regeneron Pharmaceuticals has announced five-year results from the final pre-specified overall survival (OS) analysis of the Phase III EMPOWER-Lung 1 trial. 11 September 2024
Biotechnology
Sanofi and Regeneron’s all-conquering inflammatory diseases drug Dupixent (dupilumab) has shown its worth in another disease. 11 September 2024
Biotechnology
Atara Biotherapeutics has appointed Cokey Nguyen as its new president and chief executive. 11 September 2024
Pharmaceutical
Even as emerging signs of a thaw in the broader Indian start-up funding landscape were evident, the Competition Commission of India (CCI) has tightened its exemption list under new combination rules. 11 September 2024
Pharmaceutical
Eli Lilly has announced positive results from two Phase III trials evaluating its once-weekly insulin efsitora alfa (efsitora) against the daily insulin degludec for adults with type 1 and type 2 diabetes. 11 September 2024
Biotechnology
Viridian Therapeutics has reported positive topline data from its Phase III THRIVE clinical trial of veligrotug, an intravenous treatment for thyroid eye disease (TED). 11 September 2024
Biotechnology
MAIA Biotechnology yesterday announced favorable interim survival benefit from its lead clinical candidate THIO, a telomere-targeting treatment for patients with advanced 11 September 2024
Biotechnology
US gene therapies developer Affinia Therapeutics has appointed Rami Daoud as chief business and financial officer. 11 September 2024
Pharmaceutical
New obesity drugs from public and private companies are emerging to challenge the leading positions of Denmark-based Novo Nordisk and US pharma major Eli Lilly in a GLP-1 drug market that is estimated to reach more than $200 billion in annual sales by 2031. 11 September 2024
Pharmaceutical
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
Pharmaceutical
Swiss pharma giant Roche today announced the opening of the new pharmaceutical research and development center at its global headquarters in Basel. 10 September 2024
Pharmaceutical
Roivant today announced its previously undisclosed pipeline program mosliciguat, a potential first-in-class, inhaled, once-daily sGC activator with targeted delivery to the lungs via dry powder inhaler, at Pulmovant. 10 September 2024
Biotechnology
Californian companies Gilead Sciences and Genesis Therapeutics have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. 10 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze